Consistent with the effects of HER3 overexpression, the HER3 ligand neuregulin (NRG, a.k.a Heregulin; HRG) promotes trastuzumab resistance in HER2+ breast cancer cells (Haikala and Janne, 2021). Here, ERBB2 is linked to breast carcinoma.